Dirt-dwelling microbe produces potential anti-melanoma weapon

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolite, also known as a natural product, of Streptomyces bottropensis, and its properties are important because there are not many therapies that effectively manage melanoma, the most dangerous form of skin cancer.

In the U.S. alone, more than 80,000 new melanoma cases are diagnosed each year and about 9,000 melanoma patients die. Men are more likely than women to develop melanoma; the death rate varies by race and ethnicity and is highest among white people.

Sandra Loesgen, assistant professor of chemistry and Terence Bradshaw, a scholar in OSU's College of Science, postdoctoral scholar Birte Plitzko and graduate student Elizabeth Kaweesa found that the natural product, mensacarcin, goes after melanoma cells' mitochondria - the part of a cell that creates most of the energy needed for life.

Mitochondria are also important in cell death signaling, and they have emerged as a potential target for therapy because cancer cell mitochondria are structurally and functionally different from mitochondria of non-cancerous cells.

"Mensacarcin has potent anticancer activity, with selectivity against melanoma cells," Loesgen said. "It shows powerful anti-proliferative effects in all tested cancer cell lines in the U.S. Cancer Institute's cell line panel, but inhibition of cell growth is accompanied by fast progression into cell death in only a small number of cell lines, such as melanoma cells."

To see what mensacarcin was doing to melanoma on a subcellular level, Loesgen and her team synthesized a fluorescent mensacarcin probe.

"The probe was localized to mitochondria within 20 minutes of treatment," she said. "The localization together with mensacarcin's unusual metabolic effects in melanoma cells provide evidence that mensacarcin targets mitochondria."

Live-cell bioenergetic flux analysis showed mensacarcin disturbed energy production and mitochondrial function rapidly.

"Its unique mode of action suggests it may be a useful probe for examining energy metabolism," she added. "Subsequent experiments revealed that mensacarcin rapidly alters mitochondrial pathways, resulting in mitochondrial dysfunction."

The dysfunction activates pathways to apoptosis - programmed cell death.

"Flow cytometry identified a large population of apoptotic melanoma cells, and single-cell electrophoresis indicated that mensacarcin causes genetic instability, a hallmark of early apoptosis," Loesgen said. "Mensacarcin's unique mode of action indicates it might represent a promising lead for the development of new anticancer drugs."

Findings were published recently in the Journal of Biological Chemistry.

Mensacarcin is a highly oxidized and stereogenic complex molecule that can be obtained in large amounts from its producing organism.

Natural product discoveries have contributed to many new drug leads. Loesgen points to a recent analysis of new medicines approved by the United States Food and Drug Administration between 1981 and 2014 that showed about half of all small-molecule pharmaceuticals were based on natural products or their derivatives.

Plitzko B, Kaweesa EN, Loesgen S.
The natural product mensacarcin induces mitochondrial toxicity and apoptosis in melanoma cells.
J Biol Chem. 2017 Dec 22;292(51):21102-21116. doi: 10.1074/jbc.M116.774836.

Most Popular Now

Pfizer begins a Phase 1/2 study to evaluate respir…

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV i...

Eczema drug effective against severe asthma

Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients' ability to breathe bett...

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

Novartis data at ASCO and EHA reinforce company's …

Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 ...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

Study demonstrates new treatment for severe asthma

Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering ...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...